Wilma H M Hoevenaar

Wilma H M Hoevenaar

Auto-generated profile, based on publicly available information

Wilma H M Hoevenaar

Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SESarah C. Edwards
Sarah C. Edwards
AHAnn Hedley
Ann Hedley
WHWilma H.M. Hoevenaar
Wilma H.M. Hoevenaar
RWRobert Wiesheu
Robert Wiesheu
TGTeresa Glauner
Teresa Glauner
SCSeth B. Coffelt
Seth B. Coffelt
IL-17A–producing γδ T cells in mice consist primarily of Vγ6+ tissue-resident cells and Vγ4+ circulating cells. How these γδ T cell subsets are regulated during homeostasis and cancer remains poorly understood. Using single-cell RNA sequencing and flow cytommetry, we show that lung Vγ4+ and Vγ6+ cells from tumor-free and tumor-bearing mice express contrasting cell surface molecules as well as distinct co-inhibitory molecules, which function to suppress their expansion. Vγ6+ cells express constitutively high levels of PD-1, whereas Vγ4+ cells upregulate TIM-3 in response to tumor-derived IL-1β and IL-23. Inhibition of either PD-1 or TIM-3 in mammary tumor–bearing mice increased Vγ6+ and Vγ4+ cell numbers, respectively. We found that genetic deletion of γδ T cells elicits responsiveness to anti–PD-1 and anti–TIM-3 immunotherapy in a mammary tumor model that is refractory to T cell checkpoint inhibitors, indicating that IL-17A–producing γδ T cells instigate resistance to immunotherapy. Together, these data demonstrate how lung IL-17A–producing γδ T cell subsets are differentially controlled by PD-1 and TIM-3 in steady-state and cancer.

18 November 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
ACAlastair Copland
Alastair Copland
GMGillian M Mackie
Gillian M Mackie
LSLisa Scarfe
Lisa Scarfe
EJElizabeth Jinks
Elizabeth Jinks
DLDavid A J Lecky
David A J Lecky
KMKendle M Maslowski
Kendle M Maslowski
Bacterial cancer therapy (BCT) is a promising therapeutic for solid tumours. Salmonella enterica Typhimurium (STm) is well-studied amongst bacterial vectors due to advantages in genetic modification and metabolic adaptation. A longstanding paradox is the redundancy of T cells for treatment efficacy; instead, STm BCT depends on innate phagocytes for tumour control. Here, we used distal T cell receptor (TCR) and IFNγ reporter mice ( Nr4a3 -Tocky- Ifnγ -YFP) and a colorectal cancer (CRC) model to interrogate T cell activity during BCT with attenuated STm. We found that colonic tumour infiltrating lymphocytes (TILs) exhibited a variety of activation defects, including IFN-γ production decoupled from TCR signalling, decreased polyfunctionality and reduced central memory (T CM ) formation. Modelling of T-cell–tumour interactions with a tumour organoid platform revealed an intact TCR signalosome, but paralysed metabolic reprogramming due to inhibition of the master metabolic controller, c-Myc. Restoration of c-Myc by deletion of the bacterial asparaginase ansB reinvigorated T cell activation, but at the cost of decreased metabolic control of the tumour by STm. This work shows for the first time that T cells are metabolically defective during BCT, but also that this same phenomenon is inexorably tied to intrinsic tumour suppression by the bacterial vector.

15 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
WHW.H.M. Hoevenaar
W.H.M. Hoevenaar
AJA. Janssen
A. Janssen
AQA.I. Quirindongo
A.I. Quirindongo
HMH. Ma
H. Ma
SKS. Klaasen
S. Klaasen
NJN. Jelluma
N. Jelluma
Most human cancers are aneuploid, due to a chromosomal instability (CIN) phenotype. Despite being hallmarks of cancer, however, the roles of CIN and aneuploidy in tumor formation have not unequivocally emerged from animal studies and are thus still unclear. CIN can both promote and suppress tumorigenesis, but variances in mechanisms and timings of CIN induction in different oncogenic backgrounds and associated tissues limit interpretation of the contributions of CIN. Using a novel conditional mouse model for diverse degrees of CIN, we find that a particular range is sufficient to drive very early onset spontaneous adenoma formation in the intestine, showing that CIN can act as a much more potent oncogenic driver than was previously reported. In mice predisposed to intestinal cancer ( Apc Min /+ ), moderate but not low CIN causes a remarkable increase in adenoma burden in the entire intestinal tract, especially in the distal colon, more closely modelling human disease. Strikingly, high levels of CIN promote adenoma formation in the distal colon even more than moderate CIN does, but have no effect in the small intestine. Our results thus show that CIN can be potently oncogenic, but that certain levels of CIN can have contrasting effects in distinct tissues.